Cyr61在原发性肝细胞癌中的表达及其临床意义  

Expression of Cyr61 in hepatocellular carcinoma and its clinical significance

作　　者：季君[1] 程铖[1] 周军[1] 殷月鹏[1] 高春芳[1] 

机构地区：[1]上海第二军医大学东方肝胆外科医院实验诊断科,上海200438

出　　处：《现代免疫学》2013年第3期208-212,共5页Current Immunology

基　　金：国家自然科学基金(81271925)

摘　　要：观察Cyr61在原发性肝细胞癌中表达的意义。采用酶联免疫吸附(ELISA)方法共检测380例原发性肝细胞癌患者,97例肝硬化患者和102例正常人血清中Cyr61蛋白表达水平,分析其表达与肝癌的临床病理学特征的关系。LC组Cyr61含量高于HCC组及正常对照组(P<0.001)。Cyr61表达与肝硬化、TNM分期、AFP浓度、肿瘤大小和是否存在门脉癌栓呈正相关。Cyr61可能在肝癌的发生早期发挥重要作用,并与肝癌进程中的侵袭转移有关。To observe the in situ expression of Cyr61/CCN1 in hepatocellular carcinoma （HCC） and its clinical significance, the expression of Cyr61 protein was determined by enzyme linked immunosorbent assay （ELISA） in 380 samples of human HCC serum, 97 samples of liver cirrhosis （LC） serum and 102 samples of healthy control serum. The relationship between the levels of Cyr61 expression and clinical pathological features of HCC was evaluated. The expression of Cyr61 was significantly higher in LC group than in HCC group and healthy controls （P〈0. 001）. The expression of Cyr61 was highly correlated with liver cirrhosis, TNM staging, AFP concentration, tumor size and portal vein tumor thrombus （PVTT） （P〈0. 05）. Therefore Cyr61 may play significant roles in earlier period of human HCC and may correlate with invasion and matastasis of human HCC.

关 键 词：癌 肝细胞 CYR61 CCN1 

分 类 号：R446[医药卫生—诊断学]